13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001697013
Total reported value
$1.9B
$1.9B
68 檔
21.8%
At the close of Q2 2025, Eversept Partners, LP disclosed equity holdings valued at approximately $1.9B, spread across 68 reported holdings.
In Q2 2025, Eversept Partners, LP displayed an active expansion posture, initiating 19 new positions and adding to 23 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, QQQ, GSK) accounted for 21.8% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 12.37% | -1.58% | -10.89% | |
| 2 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 8.74% | -3.49% | +16.66% | |
| 3 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 7.92% | -3.89% | -14.52% | |
| 4 | VERA | Vera Therapeutics Inc | Stock-Other | 5.16% | +0.32% | +25.50% | |
| 5 | RVTY | Revvity Inc | Stock-Healthcare | 4.54% | +0.09% | +70.63% | |
| 6 | PCVX | Vaxcyte Inc | Stock-Other | 3.88% | -0.93% | +133.10% | |
| 7 | HCA | Hca Healthcare Inc | Stock-Healthcare | 3.52% | +0.01% | -34.44% | |
| 8 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.50% | -0.38% | -3.49% | |
| 9 | BRKR | Bruker CORP | Stock-Healthcare | 3.18% | +0.35% | +68.12% | |
| 10 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.45% | +0.05% | +38.10% | |
| 11 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.14% | +0.23% | +13.90% | |
| 12 | CNC | Centene CORP | Stock-Healthcare | 1.99% | -0.19% | EXIT | |
| 13 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.96% | — | -11.78% | |
| 14 | CYH | Community Health Systems Inc | Stock-Other | 1.92% | +0.01% | -27.35% | |
| 15 | AVTR | Avantor Inc | Stock-Healthcare | 1.89% | -1.23% | EXIT | |
| 16 | TECH | Bio-techne CORP | Stock-Healthcare | 1.87% | -0.28% | +40.71% | |
| 17 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.79% | +1.50% | +61.11% | |
| 18 | ZIMV | Zimvie Inc | Stock-Other | 1.79% | — | — | |
| 19 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.74% | +0.53% | — | |
| 20 | ILMN | Illumina Inc | Stock-Healthcare | 1.74% | — | — | |
| 21 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 1.62% | — | -25.37% | |
| 22 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.57% | +0.46% | +20.42% | |
| 23 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.57% | -0.17% | +3.27% | |
| 24 | HQY | Healthequity Inc | Stock-Healthcare | 1.50% | -0.23% | EXIT | |
| 25 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 1.41% | — | — | |
| 26 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.41% | +0.37% | NEW | |
| 27 | DVAX | Dynavax Technologies CORP | Stock-Other | 1.09% | — | — | |
| 28 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.09% | — | — | |
| 29 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.00% | -0.56% | -44.41% | |
| 30 | EOLS | Evolus Inc | Stock-Other | 0.99% | — | — | |
| 31 | HUM | Humana Inc | Stock-Healthcare | 0.98% | +0.64% | NEW | |
| 32 | GERN | Geron CORP | Stock-Other | 0.95% | -0.24% | — | |
| 33 | GMED | Globus Medical Inc - A | Stock-Healthcare | 0.92% | — | -12.05% | |
| 34 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.86% | -0.40% | EXIT | |
| 35 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.69% | — | +47.51% | |
| 36 | ELV | Elevance Health Inc | Stock-Healthcare | 0.68% | — | +20.79% | |
| 37 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.64% | — | — | |
| 38 | ✓ | Merus N V | Stock-Other | 0.63% | — | +86.16% | |
| 39 | MOH | Molina Healthcare Inc | Stock-Healthcare | 0.56% | +0.73% | -13.21% | |
| 40 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.51% | — | — | |
| 41 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 42 | DHR | Danaher CORP | Stock-Healthcare | 0.43% | — | — | |
| 43 | LQDA | Liquidia CORP | Stock-Other | 0.41% | +0.42% | +138.46% | |
| 44 | GKOS | Glaukos CORP | Stock-Healthcare | 0.30% | -0.13% | -80.19% | |
| 45 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.29% | — | -26.96% | |
| 46 | NKTR | Nektar Therapeutics | Stock-Other | 0.27% | — | — | |
| 47 | ALEC | Alector Inc | Stock-Other | 0.26% | — | +221.67% | |
| 48 | AMRN | Amarin CORP PLC -adr | Stock-Other | 0.25% | +0.01% | — | |
| 49 | MNKD | Mannkind CORP | Stock-Other | 0.24% | — | — | |
| 50 | ETNBGBP | 89bio Inc | Stock-Other | 0.21% | — | -22.30% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | +1.7% | +133.10% | Add |
| 2 | UNH | Unitedhealth Group Inc | +1.7% | NEW | New buy |
| 3 | ILMN | Illumina Inc | +1.7% | NEW | New buy |
| 4 | QQQ | Invesco Qqq Trust Series 1 | +1.7% | +16.66% | Add |
| 5 | AVTR | Avantor Inc | +1.7% | +1142.57% | Add |
| 6 | IQV | Iqvia Holdings Inc | +1.4% | NEW | New buy |
| 7 | RVTY | Revvity Inc | +1.3% | +70.63% | Add |
| 8 | DVAX | Dynavax Technologies CORP | +1.1% | NEW | New buy |
| 9 | MIRM | Mirum Pharmaceuticals Inc | +1.1% | NEW | New buy |
| 10 | BRKR | Bruker CORP | +1.1% | +68.12% | Add |
| 11 | EOLS | Evolus Inc | +1% | NEW | New buy |
| 12 | GERN | Geron CORP | +1% | NEW | New buy |
| 13 | ICLR | ICON Public Limited Company | +0.7% | +495.82% | Add |
| 14 | REGN | Regeneron Pharmaceuticals | +0.6% | NEW | New buy |
| 15 | VRDN | Viridian Therapeutics Inc | +0.6% | +38.10% | Add |
| 16 | IONS | Ionis Pharmaceuticals Inc | +0.6% | +13.90% | Add |
| 17 | VERA | Vera Therapeutics Inc | +0.5% | +25.50% | Add |
| 18 | TMO | Thermo Fisher Scientific Inc | +0.5% | NEW | New buy |
| 19 | EWTX | Edgewise Therapeutics Inc | +0.5% | NEW | New buy |
| 20 | DHR | Danaher CORP | +0.4% | NEW | New buy |
| 21 | ✓ | Merus N V | +0.3% | +86.16% | Add |
| 22 | TVTX | Travere Therapeutics Inc | +0.3% | +61.11% | Add |
| 23 | CLDX | Celldex Therapeutics Inc | +0.3% | +20.42% | Add |
| 24 | NKTR | Nektar Therapeutics | +0.3% | NEW | New buy |
| 25 | AMRN | Amarin CORP PLC -adr | +0.3% | NEW | New buy |
| 26 | HUM | Humana Inc | +0.2% | +55.95% | Add |
| 27 | TECH | Bio-techne CORP | +0.2% | +40.71% | Add |
| 28 | GPCR | Structure Therapeutics Inc | +0.2% | NEW | New buy |
| 29 | LQDA | Liquidia CORP | +0.2% | +138.46% | Add |
| 30 | ALEC | Alector Inc | +0.2% | +221.67% | Add |
| 31 | RLAY | Relay Therapeutics Inc | +0.2% | NEW | New buy |
| 32 | BCYC | Bicycle Therapeutics Plc-adr | +0.1% | NEW | New buy |
| 33 | NAMS | NewAmsterdam Pharma Company N.V. | +0.1% | +47.51% | Add |
| 34 | PNTG | Pennant Group Inc/the | +0.1% | NEW | New buy |
| 35 | AUTL | Autolus Therapeutics PLC | +0.1% | +77.42% | Add |
| 36 | ARCT | Arcturus Therapeutics Holdin | +0.1% | NEW | New buy |
| 37 | MODVQ | Modivcare Inc | 0% | NEW | New buy |
| 38 | KPTI | Karyopharm Therapeutics Inc | — | — | Unchanged |
| 39 | STRO | Sutro Biopharma, Inc. | — | — | Unchanged |
| 40 | ACIU | AC Immune SA | — | — | Unchanged |
| 41 | PBYI | Puma Biotechnology Inc | — | -12.73% | Trim |
| 42 | ELV | Elevance Health Inc | 0% | +20.79% | Add |
| 43 | ETNBGBP | 89bio Inc | 0% | -22.30% | Trim |
| 44 | EHTH | Ehealth Inc | 0% | +43.83% | Add |
| 45 | 2662247D | Iteos Therapeutics Inc | 0% | -50.35% | Trim |
| 46 | RGEN | Repligen CORP | 0% | +0.91% | Add |
| 47 | IFRX | InflaRx N.V. | -0.1% | -2.12% | Trim |
| 48 | MRVI | Maravai Lifesciences Hldgs-a | -0.1% | -32.02% | Trim |
| 49 | ZBIO | Zenas Biopharma Inc | -0.1% | -26.96% | Trim |
| 50 | XOMA | Xoma Royalty Corporation | -0.1% | EXIT | Sold out |
According to official SEC Form 13F filings, Eversept Partners, LP reported a total U.S. public equity portfolio value of $1.9B across 68 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
UNH
市值: $18.9M
Top Position Liquidated / Trimmed
SPY
前期市值: $43.0M
During Q2 2025, Eversept Partners, LP's top holdings by market value included NTRA (12.4%)、QQQ (8.7%)、GSK (7.9%). The largest single position, NTRA, represented 12.4% of total portfolio value.
In Q2 2025, Eversept Partners, LP made 70 total portfolio adjustments, initiating 19 new buys, adding to 23 positions, trimming 21 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.